Premium
The prevalence of mitochondrial mutations associated with aminoglycoside‐induced sensorineural hearing loss in an NICU population
Author(s) -
Ealy Megan,
Lynch Katherine A.,
Meyer Nicole C.,
Smith Richard J.H.
Publication year - 2011
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1002/lary.21778
Subject(s) - neonatal intensive care unit , hearing loss , aminoglycoside , medicine , mitochondrial dna , intensive care unit , population , intensive care , sensorineural hearing loss , pediatrics , biology , physiology , audiology , antibiotics , genetics , intensive care medicine , gene , environmental health
Several mitochondrial DNA variants increase risk for developing sensorineural hearing loss following exposure to aminoglycoside antibiotics, a particular concern in the premature infant population, as many of these babies spend time in neonatal intensive care units and are treated with aminoglycosides. To determine the relative prevalence of five mitochondrial DNA variants in the 12S rRNA gene, MT‐RNR1 , we genotyped 703 neonatal intensive care unit patients and 1,473 individuals from the general Iowa population. We found that the aggregate frequency of these variants (∼1.8%) was comparable between populations. Although no hearing loss was detected by newborn hearing screens in the at‐risk patients, these neonatal intensive care unit graduates have an increased life‐time risk for developing aminoglycoside‐induced deafness.